HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYN

Matthew Fowler


Frontline Pembrolizumab Maintains Survival Benefit Over Chemo in PD-L1+ NSCLC

January 28, 2021

January 28, 2021 — Frontline pembrolizumab continued to demonstrate clinically meaningful improvements in overall survival, overall response rate, and time to progression on next-line therapy compared with platinum-based chemotherapy in patients with locally advanced or metastatic PD-L1–positive non–small cell lung cancer without sensitizing EGFR or ALK mutations.

Follow Up Data for IAP Antagonist Shows Improved OS for Patients with High-Risk Head and Neck Cancer

August 14, 2020

A phase 2 study found that data from a 3-year follow up showed statistically significant improvements in overall survival for patients with high-risk locally advanced squamous cell carcinoma of the head and neck treated with an IAP antagonists with chemo-radiation therapy.

CARTITUDE-1 Study Results Show Promise for Patients with Relapsed/Refractory Multiple Myeloma

June 13, 2020

Jesus G. Berdeja, MD, of the Sarah Cannon Research Institute discussed the CARTITUDE-1 study that examined CAR-T cell therapy to treat patients with relapsed/refractory multiple myeloma presented at the 2020 ASCO Virtual Scientific Program.

FDA Grants Breakthrough Therapy Designation to JNJ-6372 for NSCLC

March 12, 2020

Janssen Pharmaceutical Companies recently announced the FDA granted breakthrough therapy designation to JNJ-61186372, an EGFR-MET bispecific antibody, for the treatment of metastatic non-small cell lung cancer with EGFR exon 20 mutations.